section index links.

1.A. Patent Brokers

  • The CASM Patent Family

  • CASM Is More Foundational than Statistics and AI

  • DataSpeaks Trademark

  • CASM Has Both Open and Patent-Protected Capabilities and Applications

  • CASM Software

  • CASM Is at the Frontiers of Knowledge

  • Special Opportunities

  • Patent Broker Role

1.B. AI Providers

  • CASM for the 2026 Year of Truth in CAS Sciences AI

1.C. Academics

  • Lead Truthful Science and Trustworthy AI for CAS Sciences with Open CASM Capabilities

  • The Massive Garbage In, Garbage Out (GIGO) Problem for Statistics and AI

  • Eroom’s Law

  • Overcoming Eroom’s Law

  • The CASM First, Statistics Second Research Approach

  • Improve Decision Velocity and Patient Centricity

  • Overcome Methodological Stasis

  • AI Providers Must Lead the Way Forward

  • Academic Industry Partnerships

  • Leveraging Demands to Reduce Drug Prices

  • AI Provider Pitch to Academics

  • AI Provider Criteria for Selecting Academic Partners

1.D. Government Agencies: The Federal "Gold Standard" for CAS Metrology

1.E. Decision-Makers: Demand More from Your Evidence Providers

1.F. From ‘Group Averages for No One’ to ‘N-of-1 for Everyone’

2.A. The CASM-for-CASticity Imperative

  • CASticity for Life

  • SI and CASM Are Distinct and often Complementary Metrologies

  • Manifestations of Complex Adaptive Systematicity (CASticity)

  • Truth for Trust: How CASM Eliminates the Reductionist Blindspot in AI

  • N-of-1 Thought Leaders 

  • The Now Actionable Scientific and Technical Root Cause of Eroom’s Law

  • CASM ‘Develops’ Multivariate Time Series Data Movies

  • Mathematics-Driven, Rules-Driven, and Data-Driven Science

  • Limitations of a priori Modeling

  • Embracing Complexity with CASM

  • Need to Avoid a priori Presumptions

  • CASM for AI

  • Universal Hypotheses

  • Unsolved Problems that Statisticians Face

  • N-of-1 RCTs for Rare Diseases

  • Sample Size/Number of Repeats Tradeoffs for Statistical Significance

  • Rigor Mortis in Life Sciences

  • Avoid Possible False Negative Study Results

  • The Pervasive Why

  • Obviating the Clinical Research to Clinical Practice Translation Problem

  • GLP-1 Drug Opportunities

  • Enhancing Safety and Ethics and Reducing Liability

  • Leveraging Nested Time Scales

  • CASM Versus Granger Causality

  • Might AI Be Headed to a Dead End?

  • CASM Patent Family Ownership and Academic Partnerships

2.B. What CASM Does

  • The CASM Algorithmic Process

  • CASM Is Not a Model

  • CASM Can Vastly Expand the MTS Data Processed

  • The CASM Tripartite Definition of Work

2.C. CASM Applications

  • Longitudinal Causality Assessment (LCA)

  • Temporal Interaction Phenotypes (TIPs)

  • Diagnostic TIPs

  • Treatment and Environmental Response TIPs

  • TIPs Overview

  • Health Effects Monitoring Services (HEMS)

  • Testing Hypotheses about Individuals

  • Flipping the Script for Drug Development

  • Doubly Randomized Experimental Control

  • "Truthful and Trustworthy Science and AI" Is a Critical Public Interest

  • AI Providers Pivoting to Life Sciences

  • Doubling Down on Reductionism

  • CASM is Not What Leaders Have Been Looking For

  • Drug Repurposing and Retargeting

  • Scientific Rigor Must Embrace Truth

  • CASM for Digital Twins

  • CASM Will Disrupt AI

  • CASM Applications Are Mutually Beneficial

  • Surrogate Markers and the Reductionist Trap

  • CASM for Brains and the Persons They Live In

  • Closing the Progress and Productivity Chasm: Oncology and Psychiatry

  • The Irreducibility of Brain Temporal Interactivity

  • Might AI Be Headed to a Dead End

  • CASM Patent Family Owner and Academic Partnerships

2.D. The CASM How

  • Data Movies Over Data Snapshots

  • The Secret Sauce

  • Resistance to Longitudinal Digitization

  • Intellectual Vertigo

  • Longitudinal Digitization and Action Potentials

  • Naïve Statistics?

  • Computational Overview and CASMistry

  • Industry-University CASM Partnerships

  • Step 2: Data Pre-Processing

  • Interpolation

  • Detrending

  • Successive Differences

  • Inductive and Deductive Complexity Sciences

  • CASM First, Statistics Second for Genotype-Phenotype Mapping

  • Pre-processing fMRI MTS Data: TI Scores versus Correlation Coefficients

  • Pre-processing Waveform Data for CASM

  • Steps 3 Through 10 Overview

  • CASM Software is Cohesive

Want to learn more?

CONTACT US